Clinical Trial Detail

NCT ID NCT03499353
Title Talazoparib For Neoadjuvant Treatment Of Germline Brca1/2 Mutation Patients With Early Triple-negative Breast Cancer
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements yes
Sponsors Pfizer
Indications

triple-receptor negative breast cancer

Therapies

Talazoparib

Age Groups: adult senior

Additional content available in CKB BOOST